1358099-18-9
- CAS No.
- 1358099-18-9
- Chemical Name:
- 1358099-18-9
- Synonyms
- C25-140, 10 mM in DMSO;TRAF6-UBC13 INHIBITOR C25-140;1-(4-benzylpiperidin-1-yl)-3-(3,5-dimethyl-1-(3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl)propan-1-one;1-Propanone, 3-[3,5-dimethyl-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-1-[4-(phenylmethyl)-1-piperidinyl]-;1-(4-Benzylpiperidin-1-yl)-3-(3,5-dimethyl-1-(3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl)propan-1-one , C25-140;Ubiquitin conjugating enzyme,Ubiquitin ligase,Ubiquitin activating enzyme,C25 140,TNF Receptor,E3 ligating enzyme,C-25-140,E1/E2/E3 Enzyme,C25-140,C25140,Tumor Necrosis Factor Receptor,E2 conjugating enzyme,E1 activating enzyme,TNFR,inhibit,Inhibitor
- CBNumber:
- CB14815436
- Molecular Formula:
- C26H31N7O
- Molecular Weight:
- 457.57
- MDL Number:
- MFCD27163630
- MOL File:
- 1358099-18-9.mol
| Product description | Number | Pack Size | Price |
| C25-140 99.84% | CS-0079668 | 5mg | $180 |
| C25-140 99.84% | CS-0079668 | 10mg | $280 |
| C25-140 95.00% | INB0009817 | 5MG | $455.68 |
| C25-140 99.84% | CS-0079668 | 50mg | $990 |
| C25-140 99.84% | CS-0079668 | 100mg | $1700 |
1358099-18-9 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0079668 | C25-140 99.84% | 1358099-18-9 | 5mg | $180 | 2021-12-16 | Buy |
| ChemScene | CS-0079668 | C25-140 99.84% | 1358099-18-9 | 10mg | $280 | 2021-12-16 | Buy |
| American Custom Chemicals Corporation | INB0009817 | C25-140 95.00% | 1358099-18-9 | 5MG | $455.68 | 2021-12-16 | Buy |
| ChemScene | CS-0079668 | C25-140 99.84% | 1358099-18-9 | 50mg | $990 | 2021-12-16 | Buy |
| ChemScene | CS-0079668 | C25-140 99.84% | 1358099-18-9 | 100mg | $1700 | 2021-12-16 | Buy |
1358099-18-9 Chemical Properties,Uses,Production
Uses
C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity[1].
in vivo
C25-140 (~1.5 mg/kg; topically to the shaved back and the right ear; twice daily for 6 days) ameliorates symptoms of autoimmune psoriasis in R 837-induced psoriasis mouse model[1].
C25-140 (6-14 mg/kg; given i.p.; twice daily for 14 days) shows a dose-dependent improvement of RA disease outcome in Collagen-induced arthritis (CIA) model[1].
C25-140 (10 mg/kg; i.v.) treatment shows that the Cmax, AUC, t1/2 and Vd are 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively[1].
C25-140 (10 mg/kg; p.o.) treatment shows that the Cmax, AUC, t1/2 and Vd are 3.4 μg/mL, 124034 ng min/mL, 127.33 min and 13.3 L/kg, respectively[1].
C25-140 (10 mg/kg; i.p.) treatment shows that the Cmax, AUC, t1/2 and Vd are 4.2μg/mL, 100000 ng min/mL, 184 min, 25.6 L/kg, respectively[1].
| Animal Model: | R 837-induced psoriasis mouse model (male BALB/c mice)[1] |
| Dosage: | ~1.5 mg/kg |
| Administration: | Topically to the shaved back and the right ear; twice daily for 6 days |
| Result: | Showed a dose-dependent improvement of RA disease outcome. |
| Animal Model: | Collagen-induced arthritis (CIA) model in DBA1/J mice[1] |
| Dosage: | 6 mg/kg, 10 mg/kg, 14 mg/kg |
| Administration: | Given i.p.; twice daily for 14 days |
| Result: | Ameliorated the arthritic index to almost baseline levels in this efficacy model at doses of 10 and 14 mg/kg. Dose-dependently improved symptoms of RA including inflammation and structural damage. |
| Animal Model: | BALB/C mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | I.v. (Pharmacokinetic Analysis) |
| Result: | The Cmax, AUC, t1/2 and Vd were 9.7 μg/mL, 274083 ng min/mL, 80.62 min, and 4.13 L/kg, respectively. |
storage
Store at -20°C
References
[1] Brenke JK, et al. Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J Biol Chem. 2018 Aug 24;293(34):13191-13203. DOI:10.1074/jbc.RA118.002649
1358099-18-9 Preparation Products And Raw materials
Raw materials
Preparation Products
1358099-18-9 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Daken Advanced Materials Co.,Ltd | +86-2158073036 | info@dakenam.com | China | 13620 | 58 |
| Neostar United (Changzhou) Industrial Co., Ltd. | +86-0519-85551759 +8613506123987 | marketing1@neostarunited.com | China | 8830 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32470 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | laboratory@coreychem.com | China | 30229 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6312 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 39042 | 58 |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | masar@topule.com | China | 8467 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 | |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 12952 | 65 |
